6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December, 2003
Novogen Limited
(Translation of registrant's name into English)
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
82- ________________ .1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 3 December, 2003 By Ronald Lea Erratt, Company secretary


ASX & MEDIA RELEASE
3 DECEMBER 2003
NOVOGENS MARSHALL EDWARDS INC. SUBSIDIARY RECEIVES
US$10.1 MILLION
FROM WARRANTS EXERCISED

(Sydney, Australia, Stamford, Conn. U.S. 3 December 2003)
Novogen Limited (NASDAQ: NVGN) announced today that its
Marshall Edwards Inc. subsidiary is in receipt of
US$10.1 million from warrants exercised by Marshall Edwards
shareholders.

Novogen is also listed in Australia (ASX:NRT), and manages
its international research and development program using
the expertise and clinical research capabilities of
universities and hospitals in the U.S., Australia and
other key international locations.